Efficacy and Comparative of the Association Beclomethasone Clotrimzaol + Gentamicin in Patients With Acne Contaminated
Launched by AZIDUS BRASIL · Nov 18, 2010
Trial Information
Current as of April 28, 2025
Suspended
Keywords
ClinConnect Summary
The specific objective is to evaluate, by means of analytical propedeutics medical improvement in clinical signs and symptoms related to acne infected, the use of the association: Clotrimazole, Gentamicin and Beclomethasone versus association: Clotrimazole and Gentamicin, which will first be randomized.
The study should be conducted with 20 research subjects aged over 18 years, of both sexes, showing the framework of bilateral lesions infected with acne, at any stage of evolution. The study subjects will receive treatment with both products, so they can use one in each lesion chosen at ran...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subject search of both sexes, regardless of color or social class
- • From age to 18, with good mental health
- • Carriers of two outbreaks of acne contaminated
- • Subjects who agree to return follow-up visits
- • Research subjects who agree to participate and sign the Deed of Consent
- Exclusion Criteria:
- • Subject Research carriers of susceptibility to gentamicin
- • Research subjects suffering from sensitivity to clotrimazole
- • Research subjects suffering from sensitivity to beclomethasone
- • Research subjects who are making use of steroids or steroidal anti-inflammatory and non-steroidal drugs or who made use of topical or oral 15 days ago
- • Research subjects who are doing immunosuppressive treatment
- • Research subjects with a diagnosis of eosinophilic folliculitis or Pseudo-folliculitis barbae and groin
- • Pregnant and lactating
About Azidus Brasil
Azidus Brasil is a leading clinical research organization specializing in the development and management of clinical trials across various therapeutic areas. With a commitment to advancing healthcare, Azidus Brasil leverages its expertise in regulatory affairs, data management, and patient recruitment to deliver high-quality, efficient clinical study solutions. The organization collaborates with pharmaceutical and biotechnology companies to facilitate the successful progression of innovative therapies from initial research through to market authorization, ensuring adherence to the highest standards of ethics and scientific rigor.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Valinhos, Sp, Brazil
Patients applied
Trial Officials
Alexandre Frederico, médico
Principal Investigator
Azidus Brasil
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials